167 related articles for article (PubMed ID: 23013610)
1. Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison.
Asseburg C; Peura P; Oksanen T; Turunen J; Purmonen T; Martikainen J
Int J Technol Assess Health Care; 2012 Oct; 28(4):382-9. PubMed ID: 23013610
[TBL] [Abstract][Full Text] [Related]
2. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
McCormack PL; Foster RH
Pharmacoeconomics; 2005; 23(12):1283-98. PubMed ID: 16336021
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine.
Zhang L; Hay JW
CNS Drugs; 2005; 19(7):635-42. PubMed ID: 15984898
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Reclassifying Triptans in Australia: Application of an Economic Evaluation Approach to Regulatory Decisions.
Parkinson B; Gumbie M; Cutler H; Gauld N; Mumford V; Haywood P
Value Health; 2019 Mar; 22(3):293-302. PubMed ID: 30832967
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of oral triptan therapy in Sweden.
Ramsberg J; Henriksson M
Cephalalgia; 2007 Jan; 27(1):54-62. PubMed ID: 17212684
[TBL] [Abstract][Full Text] [Related]
6. [Economic evaluation of acute migraine attack treatment with triptans in Spain].
Gracia-Naya M; Rejas Gutiérrez J; Latorre Jiménez A; González Garcia P
Neurologia; 2005 Apr; 20(3):121-32. PubMed ID: 15815947
[TBL] [Abstract][Full Text] [Related]
7. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.
Dodick DW; Sandrini G; Williams P
CNS Drugs; 2007; 21(1):73-82. PubMed ID: 17190530
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the 'Act when Mild' study.
Slof J
Appl Health Econ Health Policy; 2012 May; 10(3):201-15. PubMed ID: 22320449
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point.
Williams P; Reeder CE
J Manag Care Pharm; 2004; 10(3):259-65. PubMed ID: 15228377
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis.
Thorlund K; Mills EJ; Wu P; Ramos E; Chatterjee A; Druyts E; Goadsby PJ
Cephalalgia; 2014 Apr; 34(4):258-67. PubMed ID: 24108308
[TBL] [Abstract][Full Text] [Related]
11. An economic evaluation of rizatriptan in the treatment of migraine.
Thompson M; Gawel M; Desjardins B; Ferko N; Grima D
Pharmacoeconomics; 2005; 23(8):837-50. PubMed ID: 16097844
[TBL] [Abstract][Full Text] [Related]
12. [Probabilistic cost-effectiveness analysis of oral eletriptan in the treatment of acute migraine in Portugal].
Félix JM; Inês MS; Acosta CM
Acta Med Port; 2005; 18(1):77-87. PubMed ID: 16202337
[TBL] [Abstract][Full Text] [Related]
13. Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy.
Kelman L; Von Seggern RL
Am J Ther; 2006; 13(5):411-7. PubMed ID: 16988536
[TBL] [Abstract][Full Text] [Related]
14. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
Cameron C; Kelly S; Hsieh SC; Murphy M; Chen L; Kotb A; Peterson J; Coyle D; Skidmore B; Gomes T; Clifford T; Wells G
Headache; 2015; 55 Suppl 4():221-35. PubMed ID: 26178694
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine.
Lofland JH; Kim SS; Batenhorst AS; Johnson NE; Chatterton ML; Cady RK; Kaniecki R; Nash DB
Mayo Clin Proc; 2001 Nov; 76(11):1093-101. PubMed ID: 11702897
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine.
Williams P; Reeder CE
Clin Ther; 2003 Nov; 25(11):2903-19. PubMed ID: 14693315
[TBL] [Abstract][Full Text] [Related]
17. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
[TBL] [Abstract][Full Text] [Related]
18. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.
Ferrari MD; Goadsby PJ; Roon KI; Lipton RB
Cephalalgia; 2002 Oct; 22(8):633-58. PubMed ID: 12383060
[TBL] [Abstract][Full Text] [Related]
19. Needle-free subcutaneous sumatriptan: in the acute treatment of migraine attacks or cluster headache episodes.
Frampton JE
CNS Drugs; 2011 Nov; 25(11):983-94. PubMed ID: 22054121
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine.
Evans KW; Boan JA; Evans JL; Shuaib A
Pharmacoeconomics; 1997 Nov; 12(5):565-77. PubMed ID: 10174323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
